Orphazyme board member on expected EMA rejection: "The next few days will be hell"

Arimoclomol has shown statistical significance as a treatment for Niemann-Pick type C, says Orphazyme Deputy Chairman of the Board Bo Jesper Hansen, who does not understand how the EMA can reject the candidate or why they have tightened up the rules for statistical significance.
Bo Jesper Hansen, deputy chair of the board, Orphazyme | Photo: Kåre Viemose
Bo Jesper Hansen, deputy chair of the board, Orphazyme | Photo: Kåre Viemose
by christopher bundgaard, translated by catherine brett

As well as holding the deputy chair position on the board of Orphazyme, Bo Jesper Hansen is something of a celebrity within the treatment of rare diseases, having also co-founded Swedish Orphan Biovitrium, Sobi.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading